Neurogene launches public offering of common stock

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage biotechnology company, announced the launch of a public offering of shares of its common stock, with pre-funded warrants available as an alternative for certain investors.

The company also plans to grant underwriters a 30-day option to purchase additional shares at the public offering price, less underwriting discounts and commissions. No terms regarding the size or pricing of the offering were disclosed. All securities are being offered by Neurogene.

According to a statement from the company, net proceeds from the offering, combined with existing cash, cash equivalents, and marketable securities, are intended to fund continued clinical development of its lead program, NGN-401, pre-commercial activities related to NGN-401, and general working capital purposes.

Leerink Partners, Stifel, Guggenheim Securities, LifeSci Capital, and William Blair are serving as joint bookrunning managers for the offering.

A shelf registration statement for the securities was filed with the Securities and Exchange Commission on March 24, 2025, and declared effective on April 4, 2025.

You May Also Be Interested In

• Aveanna selling stockholders launch 15M share secondary offering
• VirTra wins $1.5M Army contract for firearms training in Tajikistan
• Maris-Tech receives repeat order from government intelligence customer